[S02DA03, antipyrine, The serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teriflunomide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Teriflunomide.]
[L04AA27, fingolimod, Teriflunomide may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Teriflunomide.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Teriflunomide.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Teriflunomide.]
[N06DA01, tacrine, The serum concentration of Tacrine can be decreased when it is combined with Teriflunomide.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be decreased when it is combined with Teriflunomide.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Teriflunomide.]
[G03BA03, testosterone, Teriflunomide may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S03AA02, tetracycline, The excretion of Tetracycline can be decreased when combined with Teriflunomide.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Teriflunomide.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Teriflunomide.]
[R03DA07, theobromine, The serum concentration of Theobromine can be decreased when it is combined with Teriflunomide.]
[R03DA04, theophylline, The serum concentration of Theophylline can be decreased when it is combined with Teriflunomide.]
[P02CA02, thiabendazole, The serum concentration of Thiabendazole can be decreased when it is combined with Teriflunomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Teriflunomide.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Teriflunomide.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Teriflunomide.]
[N05AF04, thiothixene, The serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.]
[V04CA01, tolbutamide, The serum concentration of Tolbutamide can be increased when it is combined with Teriflunomide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Teriflunomide.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Teriflunomide.]
[C03DB02, triamterene, The serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.]
[N05AB06, trifluoperazine, The serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Teriflunomide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Teriflunomide.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Teriflunomide.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Teriflunomide.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Teriflunomide.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Teriflunomide.]
[B01AF01, rivaroxaban, Teriflunomide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Teriflunomide.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Teriflunomide.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Teriflunomide.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be decreased when used in combination with Teriflunomide.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Teriflunomide.]
[L01EC01, vemurafenib, Teriflunomide may decrease the excretion rate of Vemurafenib which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Teriflunomide.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Teriflunomide.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Teriflunomide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teriflunomide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Teriflunomide.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be decreased when it is combined with Teriflunomide.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Teriflunomide.]
[L04AX01, azathioprine, The serum concentration of Azathioprine can be decreased when it is combined with Teriflunomide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Teriflunomide.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Teriflunomide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be decreased when it is combined with Teriflunomide.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L02BB04, enzalutamide, The metabolism of Enzalutamide can be decreased when combined with Teriflunomide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Bosutinib is combined with Teriflunomide.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Teriflunomide.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Teriflunomide.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide.]
[N04BD02, rasagiline, The serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.]
[N06DA02, donepezil, Teriflunomide may decrease the excretion rate of Donepezil which could result in a higher serum level.]
[N03AX22, perampanel, The serum concentration of Perampanel can be decreased when it is combined with Teriflunomide.]
[L04AA29, tofacitinib, Teriflunomide may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The serum concentration of Zolmitriptan can be decreased when it is combined with Teriflunomide.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Teriflunomide.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Teriflunomide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Dimethyl fumarate.]
[A06AX06, tegaserod, Teriflunomide may decrease the excretion rate of Tegaserod which could result in a higher serum level.]
[R02AD01, benzocaine, The serum concentration of Benzocaine can be decreased when it is combined with Teriflunomide.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Teriflunomide.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Teriflunomide.]
[C10AC04, colesevelam, Colesevelam may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Teriflunomide.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Teriflunomide.]
[P03AX06, benzyl alcohol, The serum concentration of Benzyl alcohol can be decreased when it is combined with Teriflunomide.]
[L01EB03, afatinib, Teriflunomide may decrease the excretion rate of Afatinib which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.]
[J05AJ03, dolutegravir, Teriflunomide may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Teriflunomide.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Teriflunomide.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Teriflunomide.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J05AP08, sofosbuvir, Teriflunomide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.]
[N05CH03, tasimelteon, The serum concentration of Tasimelteon can be decreased when it is combined with Teriflunomide.]
[L04AA32, apremilast, The serum concentration of Apremilast can be decreased when it is combined with Teriflunomide.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Teriflunomide.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Siltuximab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Teriflunomide.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Teriflunomide.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Teriflunomide can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Teriflunomide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Teriflunomide.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be decreased when it is combined with Teriflunomide.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Teriflunomide.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Olaparib.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Teriflunomide.]
[N06AX11, mirtazapine, The serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Palbociclib.]
[L01EX08, lenvatinib, Teriflunomide may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Teriflunomide.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be decreased when it is combined with Teriflunomide.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Teriflunomide.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Teriflunomide.]
[J05AP06, asunaprevir, The excretion of Asunaprevir can be decreased when combined with Teriflunomide.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Teriflunomide.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Teriflunomide.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Teriflunomide.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Teriflunomide.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L01EB04, osimertinib, Teriflunomide may decrease the excretion rate of Osimertinib which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Teriflunomide.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Teriflunomide.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ixekizumab.]
[L01XX52, venetoclax, Teriflunomide may decrease the excretion rate of Venetoclax which could result in a higher serum level.]
[N05BA08, bromazepam, The serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.]
[C03CA02, bumetanide, The excretion of Bumetanide can be decreased when combined with Teriflunomide.]
[N01BB01, bupivacaine, The serum concentration of Levobupivacaine can be decreased when it is combined with Teriflunomide.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Teriflunomide.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Teriflunomide.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Teriflunomide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[S01GX07, azelastine, The serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be decreased when it is combined with Teriflunomide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Brodalumab.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be decreased when it is combined with Teriflunomide.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ocrelizumab.]
[N06BC01, caffeine, The serum concentration of Caffeine can be decreased when it is combined with Teriflunomide.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Teriflunomide.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Teriflunomide.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Teriflunomide.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Sarilumab.]
[J01MA23, delafloxacin, Teriflunomide may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Teriflunomide.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be decreased when it is combined with Teriflunomide.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Teriflunomide.]
[L01EM02, copanlisib, Teriflunomide may decrease the excretion rate of Copanlisib which could result in a higher serum level.]
[L01EF03, abemaciclib, Teriflunomide may decrease the excretion rate of Abemaciclib which could result in a higher serum level.]
[J05AG03, efavirenz, The serum concentration of Efavirenz can be decreased when it is combined with Teriflunomide.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Teriflunomide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Teriflunomide.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Teriflunomide.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N01BX04, capsaicin, The serum concentration of Capsaicin can be decreased when it is combined with Teriflunomide.]
[A10BK04, ertugliflozin, Teriflunomide may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Teriflunomide.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Teriflunomide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Teriflunomide.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teriflunomide.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Teriflunomide.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be decreased when it is combined with Teriflunomide.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Teriflunomide.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Teriflunomide.]
[N03AX17, stiripentol, The excretion of Teriflunomide can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Teriflunomide may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[L01EM04, duvelisib, Teriflunomide may decrease the excretion rate of Duvelisib which could result in a higher serum level.]
[L01EB07, dacomitinib, Teriflunomide may decrease the excretion rate of Dacomitinib which could result in a higher serum level.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be decreased when it is combined with Teriflunomide.]
[L01XK04, talazoparib, Teriflunomide may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[R03BB08, revefenacin, Teriflunomide may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Emapalumab.]
[L01AD01, carmustine, The serum concentration of Carmustine can be decreased when it is combined with Teriflunomide.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Teriflunomide.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ravulizumab.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be decreased when it is combined with Teriflunomide.]
[P02BX04, triclabendazole, The serum concentration of Triclabendazole can be decreased when it is combined with Teriflunomide.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Siponimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.]
[V03AE02, sevelamer, Sevelamer may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Teriflunomide.]
[J01DC04, cefaclor, The excretion of Cefaclor can be decreased when combined with Teriflunomide.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Teriflunomide.]
[L02BB06, darolutamide, The serum concentration of Teriflunomide can be increased when it is combined with Darolutamide.]
[L01EX15, pexidartinib, Teriflunomide may increase the hepatotoxic activities of Pexidartinib.]
[J01DC07, cefotiam, The excretion of Cefotiam can be decreased when combined with Teriflunomide.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Teriflunomide.]
[M03BX08, cyclobenzaprine, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be decreased when it is combined with Teriflunomide.]
[J01DB01, cephalexin, The excretion of Cephalexin can be decreased when combined with Teriflunomide.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Teriflunomide.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Teriflunomide.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Teriflunomide.]
[N02CC08, lasmiditan, The serum concentration of Teriflunomide can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Diroximel fumarate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Teriflunomide.]
[L01XX72, tazemetostat, Teriflunomide may decrease the excretion rate of Tazemetostat which could result in a higher serum level.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Teriflunomide.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Teriflunomide.]
[N02CC07, frovatriptan, The serum concentration of Frovatriptan can be decreased when it is combined with Teriflunomide.]
[L04AA38, ozanimod, Teriflunomide may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be decreased when it is combined with Teriflunomide.]
[M01AH02, rofecoxib, The serum concentration of Rofecoxib can be decreased when it is combined with Teriflunomide.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Teriflunomide.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Teriflunomide.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Teriflunomide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Teriflunomide.]
[L01EX17, capmatinib, The serum concentration of Teriflunomide can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluprednidene.]
[L01EX19, ripretinib, Teriflunomide may decrease the excretion rate of Ripretinib which could result in a higher serum level.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Teriflunomide is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Teriflunomide.]
[J05AX29, fostemsavir, Teriflunomide may decrease the excretion rate of Fostemsavir which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, The excretion of Belantamab mafodotin can be decreased when combined with Teriflunomide.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Teriflunomide.]
[L01EX23, pralsetinib, Teriflunomide may decrease the excretion rate of Pralsetinib which could result in a higher serum level.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Teriflunomide.]
[C10AC01, cholestyramine resin, Cholestyramine may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Teriflunomide.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Teriflunomide.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Voclosporin.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[V03AF12, trilaciclib, Teriflunomide may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be decreased when it is combined with Teriflunomide.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Teriflunomide.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Teriflunomide.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Teriflunomide.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Teriflunomide.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ponesimod.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teriflunomide.]
[A02BA01, cimetidine, The excretion of Cimetidine can be decreased when combined with Teriflunomide.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be decreased when it is combined with Teriflunomide.]
[L01XX73, sotorasib, The serum concentration of Teriflunomide can be increased when it is combined with Sotorasib.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Teriflunomide.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Pegcetacoplan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Teriflunomide.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Fexinidazole can be decreased when it is combined with Teriflunomide.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Anifrolumab.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Teriflunomide.]
[M01AG01, mefenamic acid, The serum concentration of Mefenamic acid can be decreased when it is combined with Teriflunomide.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N01BB10, levobupivacaine, The serum concentration of Levobupivacaine can be decreased when it is combined with Teriflunomide.]
[L01EJ03, pacritinib, The serum concentration of Teriflunomide can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.]
[S01EA04, clonidine, The serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Teriflunomide.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Teriflunomide.]
[J02AC06, oteseconazole, The serum concentration of Teriflunomide can be increased when it is combined with Oteseconazole.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Deucravacitinib.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be decreased when it is combined with Teriflunomide.]
[N05AH02, clozapine, The serum concentration of Clozapine can be decreased when it is combined with Teriflunomide.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Bimekizumab.]
[C10AC02, colestipol, Colestipol may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Leflunomide is combined with Teriflunomide.]
[A07BA01, activated charcoal, Activated charcoal can cause a decrease in the absorption of Teriflunomide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Teriflunomide.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Teriflunomide.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Teriflunomide.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[S01AD03, acyclovir, The serum concentration of Acyclovir can be decreased when it is combined with Teriflunomide.]
[L01EA01, imatinib, The serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.]
[N07BC04, lofexidine, The serum concentration of Lofexidine can be decreased when it is combined with Teriflunomide.]
[S01AE04, lomefloxacin, The serum concentration of Lomefloxacin can be decreased when it is combined with Teriflunomide.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Teriflunomide.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Teriflunomide.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teriflunomide.]
[S01XA18, cyclosporine, Teriflunomide may increase the immunosuppressive activities of Cyclosporine.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be increased when it is combined with Teriflunomide.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Teriflunomide.]
[J05AF10, entecavir, The serum concentration of Entecavir can be decreased when it is combined with Teriflunomide.]
[M01AH05, etoricoxib, The serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.]
[L01AX04, dacarbazine, The serum concentration of Dacarbazine can be decreased when it is combined with Teriflunomide.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Teriflunomide.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Teriflunomide.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide.]
[M01AX01, nabumetone, The serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be decreased when it is combined with Teriflunomide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Teriflunomide.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teriflunomide.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Teriflunomide.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be decreased when it is combined with Teriflunomide.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Teriflunomide.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Teriflunomide.]
[N06AB05, paroxetine, The serum concentration of Paroxetine can be decreased when it is combined with Teriflunomide.]
[B01AC04, clopidogrel, The serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be decreased when it is combined with Teriflunomide.]
[S01BC03, diclofenac, The serum concentration of Diclofenac can be decreased when it is combined with Teriflunomide.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Teriflunomide.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Teriflunomide.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Teriflunomide.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Difluocortolone.]
[C01AA05, digoxin, The excretion of Digoxin can be decreased when combined with Teriflunomide.]
[C02DB01, dihydralazine, The serum concentration of Dihydralazine can be decreased when it is combined with Teriflunomide.]
[C10AX09, ezetimibe, Teriflunomide may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teriflunomide.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Teriflunomide.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Teriflunomide.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Teriflunomide.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be decreased when it is combined with Teriflunomide.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Teriflunomide.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be decreased when it is combined with Teriflunomide.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Teriflunomide.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Teriflunomide.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Teriflunomide.]
[C01BA03, disopyramide, The serum concentration of Disopyramide can be decreased when it is combined with Teriflunomide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.]
[N07XX02, riluzole, The serum concentration of Riluzole can be decreased when it is combined with Teriflunomide.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Teriflunomide.]
[N01BB09, ropivacaine, The serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Teriflunomide.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Teriflunomide.]
[C02KX02, ambrisentan, The excretion of Ambrisentan can be decreased when combined with Teriflunomide.]
[A03FA03, domperidone, The serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.]
[N06AA12, doxepin, The serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Teriflunomide.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Teriflunomide.]
[N02CC01, sumatriptan, Teriflunomide may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Teriflunomide.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Teriflunomide.]
[J01MA05, temafloxacin, The serum concentration of Temafloxacin can be decreased when it is combined with Teriflunomide.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Teriflunomide.]
[D01BA02, terbinafine, The serum concentration of Terbinafine can be decreased when it is combined with Teriflunomide.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Teriflunomide.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Teriflunomide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Teriflunomide.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Trofosfamide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Teriflunomide.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Teriflunomide.]
[N05CF02, zolpidem, The serum concentration of Zolpidem can be decreased when it is combined with Teriflunomide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Teriflunomide.]
[N05AX11, zotepine, The serum concentration of Zotepine can be decreased when it is combined with Teriflunomide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Teriflunomide.]
[S01AA17, erythromycin, The excretion of Erythromycin can be decreased when combined with Teriflunomide.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[H05BX01, cinacalcet, The serum concentration of Cinacalcet can be decreased when it is combined with Teriflunomide.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Teriflunomide.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Teriflunomide.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Conjugated estrogens can be decreased when it is combined with Teriflunomide.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Teriflunomide.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Teriflunomide.]
[L01CB01, etoposide, The serum concentration of Etoposide can be decreased when it is combined with Teriflunomide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Teriflunomide.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.]
[C01BB03, tocainide, The serum concentration of Tocainide can be decreased when it is combined with Teriflunomide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Teriflunomide.]
[C10AA03, pravastatin, The excretion of Pravastatin can be decreased when combined with Teriflunomide.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teriflunomide.]
[A02BA03, famotidine, The excretion of Famotidine can be decreased when combined with Teriflunomide.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Teriflunomide.]
[P02CA03, albendazole, The serum concentration of Albendazole can be decreased when it is combined with Teriflunomide.]
[N03AX26, fenfluramine, The serum concentration of Fenfluramine can be decreased when it is combined with Teriflunomide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Teriflunomide.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Teriflunomide.]
[C01BC04, flecainide, The serum concentration of Flecainide can be decreased when it is combined with Teriflunomide.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Teriflunomide.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Teriflunomide.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Teriflunomide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocortolone.]
[V03AZ01, ethanol, The serum concentration of Ethanol can be decreased when it is combined with Teriflunomide.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Teriflunomide.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Teriflunomide.]
[L01BC02, fluorouracil, The serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide.]
[N06AB03, fluoxetine, The serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.]
[L02BB01, flutamide, The serum concentration of Flutamide can be decreased when it is combined with Teriflunomide.]
[V04CX02, folic acid, Teriflunomide may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The serum concentration of Tegafur can be decreased when it is combined with Teriflunomide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Teriflunomide.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be decreased when it is combined with Teriflunomide.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Teriflunomide.]
[A10BB01, glyburide, Teriflunomide may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be decreased when it is combined with Teriflunomide.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Teriflunomide.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Teriflunomide.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Teriflunomide.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Teriflunomide.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Teriflunomide.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Teriflunomide.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Teriflunomide.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Teriflunomide.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Teriflunomide.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Teriflunomide.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Teriflunomide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Teriflunomide.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Teriflunomide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Teriflunomide.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Tixocortol.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Teriflunomide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Teriflunomide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teriflunomide.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Teriflunomide.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Teriflunomide.]
[N05CH02, ramelteon, The serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Teriflunomide.]
[L01XX35, anagrelide, The serum concentration of Anagrelide can be decreased when it is combined with Teriflunomide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teriflunomide.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Teriflunomide.]
[J05AB13, penciclovir, The serum concentration of Penciclovir can be decreased when it is combined with Teriflunomide.]
[P02CF01, ivermectin, Teriflunomide may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Teriflunomide.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Teriflunomide.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Teriflunomide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Teriflunomide.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Teriflunomide.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Teriflunomide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Teriflunomide.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Temsirolimus is combined with Teriflunomide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Teriflunomide.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Teriflunomide.]
[N06AA21, maprotiline, The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Teriflunomide.]
[N05CH01, melatonin, The serum concentration of Melatonin can be decreased when it is combined with Teriflunomide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Teriflunomide.]
[N03AB04, mephenytoin, The serum concentration of Mephenytoin can be decreased when it is combined with Teriflunomide.]
[J05AF05, lamivudine, Teriflunomide may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Teriflunomide.]
[L01BA04, pemetrexed, Teriflunomide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Teriflunomide.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be decreased when it is combined with Teriflunomide.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be decreased when it is combined with Teriflunomide.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Teriflunomide.]
[A03FA01, metoclopramide, The serum concentration of Metoclopramide can be decreased when it is combined with Teriflunomide.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be decreased when it is combined with Teriflunomide.]
[N06AX03, mianserin, The serum concentration of Mianserin can be decreased when it is combined with Teriflunomide.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be decreased when it is combined with Teriflunomide.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Teriflunomide.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Teriflunomide.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Teriflunomide.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Teriflunomide.]
[N06AA09, amitriptyline, The serum concentration of Amitriptyline can be decreased when it is combined with Teriflunomide.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Teriflunomide.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The serum concentration of Eltrombopag can be decreased when it is combined with Teriflunomide.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Teriflunomide.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Teriflunomide.]
[G03XC01, raloxifene, Teriflunomide may decrease the excretion rate of Raloxifene which could result in a higher serum level.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Teriflunomide.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teriflunomide.]
[N04BC04, ropinirole, The metabolism of Ropinirole can be increased when combined with Teriflunomide.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Teriflunomide.]
[M02AA12, naproxen, The serum concentration of Naproxen can be decreased when it is combined with Teriflunomide.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Teriflunomide.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Teriflunomide.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Teriflunomide.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Teriflunomide.]
[M04AA03, febuxostat, The excretion of Teriflunomide can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Teriflunomide.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be decreased when combined with Teriflunomide.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.]
[J01XE01, nitrofurantoin, Teriflunomide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[C02KX01, bosentan, The excretion of Bosentan can be decreased when combined with Teriflunomide.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Teriflunomide.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Teriflunomide.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Teriflunomide.]
[S01AA04, oxytetracycline, The excretion of Oxytetracycline can be decreased when combined with Teriflunomide.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Teriflunomide.]
[N05AH05, asenapine, The serum concentration of Asenapine can be decreased when it is combined with Teriflunomide.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Teriflunomide.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Teriflunomide.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Teriflunomide.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Teriflunomide.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be decreased when it is combined with Teriflunomide.]
[N05AB03, perphenazine, The serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Teriflunomide.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be decreased when it is combined with Teriflunomide.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Teriflunomide.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Teriflunomide.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Teriflunomide.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Teriflunomide.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Teriflunomide.]
[N05AG02, pimozide, The serum concentration of Pimozide can be decreased when it is combined with Teriflunomide.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Teriflunomide.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Teriflunomide.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Teriflunomide.]
[J01MA11, grepafloxacin, The serum concentration of Grepafloxacin can be decreased when it is combined with Teriflunomide.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Teriflunomide.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Teriflunomide.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Teriflunomide.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Teriflunomide.]
[A03AE01, alosetron, The serum concentration of Alosetron can be decreased when it is combined with Teriflunomide.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Teriflunomide.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Teriflunomide.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Teriflunomide.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Teriflunomide.]
[P02BA01, praziquantel, The serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide.]
[C02CA01, prazosin, Teriflunomide may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Teriflunomide.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Teriflunomide.]
[P01BA03, primaquine, The serum concentration of Primaquine can be decreased when it is combined with Teriflunomide.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Teriflunomide.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Teriflunomide which could result in a higher serum level.]
[N05AA03, promazine, The serum concentration of Promazine can be decreased when it is combined with Teriflunomide.]
[C01BC03, propafenone, The serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Teriflunomide.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Teriflunomide.]
[C07AA05, propranolol, The serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teriflunomide.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Teriflunomide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Teriflunomide.]
[P01BC01, quinine, The serum concentration of Quinine can be decreased when it is combined with Teriflunomide.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be decreased when it is combined with Teriflunomide.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Teriflunomide.]
[N04BD01, selegiline, The serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teriflunomide.]
[N03AG01, valproic acid, The excretion of Valproic acid can be decreased when combined with Teriflunomide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone butyrate.]
